Steve Jackson

Steve Jackson is one of the world's leading authorities on DNA repair and the DNA damage response in cancer. His laboratory made foundational discoveries establishing how cells detect DNA double-strand breaks through ATM kinase activation, characterized the DNA-PK complex in non-homologous end joining, and elucidated the molecular mechanisms of homologous recombination repair. He co-founded KuDOS Pharmaceuticals to develop PARP inhibitors as cancer therapeutics based on the synthetic lethality concept in BRCA-deficient cells, work that ultimately led to the development of olaparib. His decades of research on DNA repair mechanisms have been foundational to the entire PARP inhibitor field.